Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis

被引:3
|
作者
Solis-Tarazona, Luis [1 ]
Raket, Lars Lau [2 ]
Cabello-Murgui, Javier [1 ]
Reddam, Salma [1 ]
Navarro-Quevedo, Silvia [3 ]
Gil-Perotin, Sara [1 ,4 ,5 ]
机构
[1] Inst Invest Sanitaria La Fe, Res Grp Immunotherapy & Biomodels Autoimmun, Valencia, Spain
[2] Lund Univ, Dept Clin Sci, Clin Memory Res Unit, Lund, Sweden
[3] Hosp Univ & Politecn La Fe, Neurol, Valencia, Spain
[4] Hosp Univ & Politecn La Fe, Multiple Sclerosis Unit, Neurol, Valencia, Spain
[5] Inst Salud Carlos III, Consorcio Ctr Invest Biomed Red CIBER, CB06-05-1131, Madrid, Spain
来源
FRONTIERS IN NEUROLOGY | 2024年 / 15卷
关键词
multiple sclerosis; biomarker; relapse; Z-score; RMS; CEREBROSPINAL-FLUID; DISABILITY;
D O I
10.3389/fneur.2024.1354431
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The assessment of serum neurofilament light chain (sNFL) has emerged as a diagnostic and prognostic tool in monitoring multiple sclerosis (MS). However, the application of periodic measurement in daily practice remains unclear.Objective To evaluate the predictive value of individual sNFL levels in determining disease activity in patients with relapsing MS (RMS).Methods In this two-year prospective study, 129 RMS patients underwent quarterly sNFL assessments and annual MRI scans. The study analyzed the correlation between individual NFL levels and past, current, and future disease activity. Group-level Z-scores were employed as a comparative measure.Results Among the 37 participants, a total of 61 episodes of disease activity were observed. sNFL levels proved valuable in distinct ways; they were confirmatory of previous and current clinical and/or radiological activity and demonstrated a high negative predictive value for future 90 days activity. Interestingly, Z-scores marginally outperformed sNFL levels in terms of predictive accuracy, indicating the potential for alternative approaches in disease activity assessment. In our cohort, sNFL cut-offs of 10.8 pg./mL (sensitivity 27%, specificity 90%) and 14.3 pg./mL (sensitivity 15%, specificity 95%) correctly identified 7 and 4 out of 26 cases of radiological activity within 90 days, respectively, with 14 and 15% false negatives. When using lower cut-off values, individuals with sNFL levels below 5 pg/mL (with a sensitivity of 92%, specificity of 25%, and negative predictive value of 94%) were less likely to experience radiological activity within the next 3 months.Conclusion Individual sNFL levels may potentially confirm prior or current disease activity and predict short-term future radiological activity in RMS. These findings underscore its periodic measurement as a valuable tool in RMS management and decision-making, enhancing the precision of clinical evaluation in routine practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis
    Bsteh, Gabriel
    Berek, Klaus
    Hegen, Harald
    Buchmann, Arabella
    Voortman, Margarete M.
    Auer, Michael
    Wurth, Sebastian
    Zinganell, Anne
    Di Pauli, Franziska
    Deisenhammer, Florian
    Khalil, Micheal
    Berger, Thomas
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (04)
  • [32] Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort
    Arroyo Pereiro, Pablo
    Munoz-Vendrell, Albert
    Leon Moreno, Isabel
    Bau, Laura
    Matas, Elisabet
    Romero-Pinel, Lucia
    Yelamos, Antonio Martinez
    Yelamos, Sergio Martinez
    Andres-Benito, Pol
    JOURNAL OF NEUROLOGY, 2024, 271 (03) : 1495 - 1496
  • [33] Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
    Kuhle, Jens
    Plavina, Tatiana
    Barro, Christian
    Disanto, Giulio
    Sangurdekar, Dipen
    Singh, Carol M.
    de Moor, Carl
    Engle, Bob
    Kieseier, Bernd C.
    Fisher, Elizabeth
    Kappos, Ludwig
    Rudick, Richard A.
    Goyal, Jaya
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (13) : 1691 - 1699
  • [34] Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients
    Paolicelli, Damiano
    Ruggieri, Maddalena
    Manni, Alessia
    Gargano, Concetta D. D.
    Carleo, Graziana
    Palazzo, Claudia
    Iaffaldano, Antonio
    Bollo, Luca
    Guerra, Tommaso
    Saracino, Annalisa
    Frigeri, Antonio
    Iaffaldano, Pietro
    Trojano, Maria
    BRAIN SCIENCES, 2022, 12 (12)
  • [35] Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
    Reinert, Marie-Christine
    Benkert, Pascal
    Wuerfel, Jens
    Michalak, Zuzanna
    Ruberte, Esther
    Barro, Christian
    Huppke, Peter
    Stark, Wiebke
    Kropshofer, Harald
    Tomic, Davorka
    Leppert, David
    Kuhle, Jens
    Bruck, Wolfgang
    Gartner, Jutta
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (04):
  • [36] Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?
    Saposnik, Gustavo
    Monreal, Enric
    Medrano, Nicolas
    Garcia-Dominguez, Jose M.
    Querol, Luis
    Meca-Lallana, Jose E.
    Landete, Lamberto
    Salas, Elisa
    Meca-Lallana, Virginia
    Garcia-Arcelay, Elena
    Aguera-Morales, Eduardo
    Martinez-Yelamos, Sergio
    Gomez-Ballesteros, Rocio
    Maurino, Jorge
    Villar, Luisa M.
    Caminero, Ana B.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 90
  • [37] Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis
    Meier, Stephanie
    Willemse, Eline A. J.
    Schaedelin, Sabine
    Oechtering, Johanna
    Lorscheider, Johannes
    Melie-Garcia, Lester
    Cagol, Alessandro
    Barakovic, Muhamed
    Galbusera, Riccardo
    Subramaniam, Suvitha
    Barro, Christian
    Abdelhak, Ahmed
    Thebault, Simon
    Achtnichts, Lutz
    Lalive, Patrice
    Muller, Stefanie
    Pot, Caroline
    Salmen, Anke
    Disanto, Giulio
    Zecca, Chiara
    D'Souza, Marcus
    Orleth, Annette
    Khalil, Michael
    Buchmann, Arabella
    Du Pasquier, Renaud
    Yaldizli, Ozgur
    Derfuss, Tobias
    Berger, Klaus
    Hermesdorf, Marco
    Wiendl, Heinz
    Piehl, Fredrik
    Battaglini, Marco
    Fischer, Urs
    Kappos, Ludwig
    Gobbi, Claudio
    Granziera, Cristina
    Bridel, Claire
    Leppert, David
    Maceski, Aleksandra Maleska
    Benkert, Pascal
    Kuhle, Jens
    JAMA NEUROLOGY, 2023, 80 (03) : 287 - 297
  • [38] Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
    Revendova, Kamila Zondra
    Cucuzza, Chiara Starvaggi
    Manouchehrinia, Ali
    Khademi, Mohsen
    Bar, Michal
    Leppert, David
    Sandberg, Elisabeth
    Ouellette, Russell
    Granberg, Tobias
    Piehl, Fredrik
    BRAIN AND BEHAVIOR, 2023, 13 (01):
  • [39] Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
    Kuhle, Jens
    Barro, Christian
    Disanto, Giulio
    Mathias, Amandine
    Soneson, Charlotte
    Bonnier, Guillaume
    Yaldizli, Oezguer
    Regeniter, Axel
    Derfuss, Tobias
    Canales, Mathieu
    Schluep, Myriam
    Du Pasquier, Renaud
    Krueger, Gunnar
    Granziera, Cristina
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (12) : 1550 - 1559
  • [40] Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis
    Chitnis, Tanuja
    Gonzalez, Cindy
    Healy, Brian C.
    Saxena, Shrishti
    Rosso, Mattia
    Barro, Christian
    Michalak, Zuzanna
    Paul, Anu
    Kivisakk, Pia
    Diaz-Cruz, Camilo
    Sattarnezhad, Neda
    Pierre, Isabelle V.
    Glanz, Bonnie I.
    Tomic, Davorka
    Kropshofer, Harald
    Haring, Dieter
    Leppert, David
    Kappos, Ludwig
    Bakshi, Rohit
    Weiner, Howard L.
    Kuhle, Jens
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2018, 5 (12): : 1478 - 1491